University of Patras
Μελέτη του ρόλου των φαρμακογονιδιωματικών δεικτών στην εξατομίκευση της θεραπείας σχιζοφρενικών και συναισθηματικών ψυχώσεων
Abstract
dc:descriptionSchizophrenia is the most serious psychiatric disorder that affects about 1% of people worldwide and so far, its etiology is still unknown. In this study, we first conducted a systematic literature survey of articles investigating a possible association between genetic variants in candidate genes and the variable treatment response of schizophrenia patients under risperidone and clozapine treatment. Forty-nine studies, involving 6,786 controls and 5,705 patients with schizophrenia of Caucasian, Han Chinese, Japanese, Korean and Afro-American origin, were collected and meta-analyzed. Our meta-analysis revealed that the two SNPs, rs6313 and rs1799978 found in HTR2A and DRD2 receptor genes respectively were associated with clozapine treatment efficacy. To confirm these findings, we genotyped 413 SZ cases and 340 controls of Greek, Slovenian and Croatian descent for those variants, using PCR-RFLP, Sanger Sequencing, and SimpleProbe Analysis. Our data show that rs6313 is associated with patients’ response to atypical antipsychotics. Overall, our findings suggest that rs6313 can be potentially useful as a pharmacogenomic biomarker for risperidone and clozapine treatment of SZ patients.Bipolar disorder is a severe psychiatric disorder affecting 1% to 3% of the general population. Lithium is the first line therapy for long term management of BD, being effective in preventing depression and mania and reducing the risk of suicide. Studies have shown that the use of Li+ in clinical psychiatry may be associated with a reduction of eGFR in patients with long-term Li+ treatment. The aim of our study was to identify genetic variants associated with Li+-induced eGFR in a sample of Sardinian bipolar patients under long-term Li+ treatment. For this reason, tag SNPs from genes previously shown to be associated with kidney dysfunction or Li+ metabolism were selected and genotyped using the Invader assay and Sanger sequencing. According to our results, rs378448, located in ACCN1 (or ASIC2) gene, previously shown by our group to be associated with Li+ treatment response in bipolar disease patients, was significantly associated with Li+-induced reduction of eGFR, while statistical significance remained after adjustment of pvalue for variables like age, gender, smoking habits and years or Li treatment. In conclusion, our findings provide preliminary evidence that rs378448 may constitute potential predictor for a better use of Li and increase safety in treatment of bipolar patients.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsermpini, Evangelia-Eirini
- Τσερμπίνι, Ευαγγελία-Ειρήνη
Subjects
dc:subject × 16Rights
dc:rights- Statement dc:rights
-
- BY_NC
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/39703